Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104505 | 0.88 | TACR2 (0.44) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5105055 | 0.88 | NPSR1 (0.44) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5105484 | 0.86 | TACR2 (0.43) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5104941 | 0.86 | TACR2 (0.42) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5110617 | 0.85 | TACR2 (0.43) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5097697 | 0.85 | TACR2 (0.40) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5105669 | 0.84 | TACR2 (0.42) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5110413 | 0.84 | TACR2 (0.43) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5102039 | 0.84 | TACR2 (0.40) | TACR2POLBNPSR1NPC1KDM4E | |
| SCHEMBL5111935 | 0.84 | NPSR1 (0.45) | TACR2POLBNPSR1NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342027-B2 | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2008-03-11 | — | — | US | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
| WO-2004011457-A1 | 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | TACR2 3647/4885POLB 4036/4885NPSR1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.